T. Rowe Price and OrbiMed News

This is selected news for T. Rowe Price and OrbiMed, which are filed under Capital Firms and Sectors / Healthtech, respectively. There are 14 news items for this page.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
10/18/2022 Venture Capital: Under-The -Radar Oncology Start-up Treeline Biosciences Nabs $261M
... in high-growth health care-related companies. Other investors included Rock Springs Capital, ARCH Venture Partners, GV, OrbiMed, Access Industries, funds and accounts advised by T. Rowe Price Associates, Inc., Ajax Health/Zeus, Casdin Capital and Aisling Capital. ‚AuWhile we‚Aove made significant progress in building the pipeline we envisioned ...
dailyalts.com
10/14/2022 Odyssey Therapeutics secures $168m in Series B financing round
... Healthcare Innovation Investment Fund, an investment fund associated with SVB Securities, and other institutional investors. It also includes participation from all Series A investors, including OrbiMed, SR One, Foresite Capital, Logos Capital, Woodline Partners, HBM Healthcare Investments, Colt Ventures and Creacion Ventures. Odyssey Therapeutics founder and CEO Gary Glick said ...
ns-healthcare.com
10/13/2022 Odyssey Therapeutics Announces Oversubscribed $168 Million Series B Financing
... sector. Other new investors participating in the Series B financing include funds and accounts advised by Fidelity Management & Research Company, funds and accounts advised by T. Rowe Price Associates, Inc., GreatPoint Ventures, Catalio Capital Management, Walleye Capital, Alexandria Venture Investments, The Healthcare Innovation Investment Fund LLC, an investment fund associated ...
PR Newswire
10/13/2022 Odyssey Therapeutics Announces Oversubscribed $168 Million Series B Financing
... Fund LLC, an investment fund associated with SVB Securities LLC, and other institutional investors. The financing also includes participation from all Series A investors including OrbiMed, SR One, Foresite Capital, Logos Capital, Woodline Partners LP, HBM Healthcare Investments, Colt Ventures and Creacion Ventures. ‚AuOdyssey is pioneering next generation therapeutics by ...
roboticulized.com
10/13/2022 Odyssey Therapeutics raises $168M for oncology medicine portfolio
... Catalyst. Other new investors participating in the Series B financing include funds and accounts advised by Fidelity Management & Research Company, funds and accounts advised by T. Rowe Price Associates, Inc., GreatPoint Ventures, Catalio Capital Management, Walleye Capital, Alexandria Venture Investments, The Healthcare Innovation Investment Fund LLC, an investment fund associated ...
labiotech.eu
10/13/2022 Odyssey Therapeutics Raises $168M in Series B Financing
... from Fidelity Management & Research Company, T. Rowe Price Associates, GreatPoint Ventures, Catalio Capital Management, Walleye Capital, Alexandria Venture Investments, The Healthcare Innovation Investment Fund LLC, OrbiMed, SR One, Foresite Capital, Logos Capital, Woodline Partners LP, HBM Healthcare Investments, Colt Ventures and Creacion Ventures. The company intends to use the funds ...
finsmes.com
4/13/2021 Theseus Debuts with $100 Million Series B to for Targeted Treatment-Resistant Cancer Mutations
... with participation from Adage Capital Management, Boxer Capital, Farallon Capital Management, Longitude Capital, Nextech Ventures, Omega Healthcare Investors, Pontifax Venture Capital, Rock Springs Capital, and T. Rowe Price, as well as OrbiMed, which incubated Theseus and funded its series A round in 2018. In conjunction with the financing, Michael Rome ...
globalgenes.org
3/31/2021 Scribe Therapeutics Raises $100M Series B Financing to Further Develop “CRISPR by Design” Platform and Pipeline of Breakthrough Genetic Medicines
... based genetic medicine, today announced the completion of an oversubscribed $100M Series B financing. Avoro Ventures and Avoro Capital Advisors led the financing joined by OrbiMed Advisors and Andreessen Horowitz. Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., funds managed by Wellington Management, RA Capital Management ...
Business Wire
3/31/2021 Scribe Therapeutics Raises $100M Series B Financing to Further Develop "CRISPR by Design" Platform and Pipeline of Breakthrough Genetic Medicines
... B financing. Avoro Ventures and Avoro Capital Advisors led the financing joined by OrbiMed Advisors and Andreessen Horowitz. Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., funds managed by Wellington Management, RA Capital Management, Menlo Ventures, and an undisclosed global investment firm also joined the syndicate ...
Yahoo News
3/31/2021 Scribe Raises $100 Million to Further Develop Its “CRISPR by Design” Platform
Rare Daily Staff Scribe Therapeutics completed an oversubscribed $100 million series B financing to continue developing its ‚AuCRISPR by Design‚Au platform and its pipeline of genetic medicines. Avoro Ventures and Avoro Capital Advisors led the financing joined by OrbiMed Advisors and Andreessen Horowitz. Perceptive Advisors, funds and accounts advised ...
globalgenes.org
3/31/2021 Scribe Therapeutics Raises $100M Series B Financing to Further Develop “CRISPR by Design” Platform and Pipeline of Breakthrough Genetic Medicines
... B financing. Avoro Ventures and Avoro Capital Advisors led the financing joined by OrbiMed Advisors and Andreessen Horowitz. Perceptive Advisors, funds and accounts advised by T. Rowe Price Associates, Inc., funds managed by Wellington Management, RA Capital Management, Menlo Ventures, and an undisclosed global investment firm also joined the syndicate ...
vcaonline.com
3/31/2021 Scribe Therapeutics Raises $100M Series B Financing to Further Develop CRISPR by Design Platform and Pipeline of Breakthrough Genetic Medicines
Scribe Therapeutics Inc., a molecular engineering company creating the most advanced technologies for CRISPR-based genetic medicine, today announced the completion of an oversubscribed $100M Series B financing. Avoro Ventures and Avoro Capital Advisors led the financing joined by OrbiMed Advisors and Andreessen Horowitz. Perceptive Advisors, funds and accounts advised ...
financialbuzz.com
10/27/2020 Caris Life Sciences Raises $310 Million in Growth Capital from a Broad Syndicate of Leading Investors
... capital. The financing includes $235 million in equity financing co-led by Highland Capital Management and Coatue, with participation from funds and accounts advised by T. Rowe Price Associates, Inc., OrbiMed, Millennium Management, Neuberger Berman, ClearBridge Investments, First Light Asset Management and other undisclosed investors. The Company also raised $75 ...
BioSpace
10/27/2020 Caris Life Sciences Raises $310 Million in Growth Capital from a Broad Syndicate of Leading Investors
... million in equity financing co-led by Highland Capital Management and Coatue, with participation from funds and accounts advised by T. Rowe Price Associates, Inc., OrbiMed, Millennium Management, Neuberger Berman, ClearBridge Investments, First Light Asset Management and other undisclosed investors. The Company also raised $75 million in debt from Sixth ...
vcaonline.com
7/9/2020 VelosBio Raises $137M in Series B
... B financing round include Adage Capital Management LP, Cormorant Asset Management, Farallon, Foresite Capital, Janus Henderson Investors, Logos Capital, OrbiMed, funds and accounts advised by T. Rowe Price Associates, Inc., Venrock Healthcare Capital Partners, Viking Global Investors, and Wellington Management Company, which are joining existing investors Arix Bioscience, Decheng Capital ...
vcnewsdaily.com
7/8/2020 VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology
... New investors participating in the Series B financing round include Adage Capital Management LP, Cormorant Asset Management, Farallon, Foresite Capital, Janus Henderson Investors, Logos Capital, OrbiMed, funds and accounts advised by T. Rowe Price Associates, Inc., Venrock Healthcare Capital Partners, Viking Global Investors, and Wellington Management Company, which are joining ...
Business Wire
7/8/2020 VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology
... B financing round include Adage Capital Management LP, Cormorant Asset Management, Farallon, Foresite Capital, Janus Henderson Investors, Logos Capital, OrbiMed, funds and accounts advised by T. Rowe Price Associates, Inc., Venrock Healthcare Capital Partners, Viking Global Investors, and Wellington Management Company, which are joining existing investors Arix Bioscience, Decheng Capital ...
BioSpace
7/8/2020 VelosBio Raises $137 Million in Series B Financing to Advance Development of ROR1-Directed Therapeutics in Oncology
... Management and Surveyor Capital (a Citadel company) are joined by Adage Capital Management LP, Cormorant Asset Management, Farallon, Foresite Capital, Janus Henderson Investors, Logos Capital, OrbiMed, funds and accounts advised by T. Rowe Price Associates, Inc., Venrock Healthcare Capital Partners, Viking Global Investors, Wellington Management Company, and all existing institutional ...
vcaonline.com
7/8/2020 VelosBio raises $137M Series B round to support suite of ROR1-targeting cancer drugs
The company is currently running a Phase I study of its lead candidate, the antibody-drug conjugate VLS-101, in patients with lymphomas and leukemias. It has two additional antibody-drug conjugates and a bispecific antibody in preclinical development ...
MedCity News